Yahoo
OTC Markets OTCQB - Delayed Quote USD

Shield Therapeutics plc (SHIEF)

0.0736 0.0000 (0.00%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for SHIEF
  • Previous Close 0.0736
  • Open 0.0699
  • Bid 0.0691 x 1000000
  • Ask 0.0986 x 3000000
  • Day's Range 0.0699 - 0.0704
  • 52 Week Range 0.0521 - 0.1679
  • Volume 16,237
  • Avg. Volume 2,565
  • Market Cap (intraday) 79.058M
  • Beta (5Y Monthly) 1.73
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0100
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, United Kingdom.

www.shieldtherapeutics.com

61

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

SHIEF
45.28%
FTSE 100 (^FTSE)
8.04%

1-Year Return

SHIEF
24.51%
FTSE 100 (^FTSE)
9.94%

3-Year Return

SHIEF
0.54%
FTSE 100 (^FTSE)
46.43%

5-Year Return

SHIEF
85.28%
FTSE 100 (^FTSE)
48.25%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -17.69%

  • Return on Assets (ttm)

    -4.37%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    58.62M

  • Net Income Avi to Common (ttm)

    -10.37M

  • Diluted EPS (ttm)

    -0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.35M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -3.21M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: